4D Molecular Therapeutics (FDMT) Net Cash Flow (QoQ) (2020 - 2026)
4D Molecular Therapeutics (FDMT) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.80% |
| Dec 31, 2025 | 140.85% |
| Sep 30, 2025 | 49.25% |
| Jun 30, 2025 | -256.53% |
| Mar 31, 2025 | 58.62% |
| Dec 31, 2024 | -2,410.05% |
| Sep 30, 2024 | 98.24% |
| Jun 30, 2024 | -426.71% |
| Mar 31, 2024 | 199.68% |
| Dec 31, 2023 | -167.49% |
| Sep 30, 2023 | -75.04% |
| Jun 30, 2023 | 501.66% |
| Mar 31, 2023 | 146.86% |
| Dec 31, 2022 | -978.81% |
| Sep 30, 2022 | -113.82% |
| Jun 30, 2022 | 148.70% |
| Mar 31, 2022 | -224.22% |
| Dec 31, 2021 | 140.60% |
| Sep 30, 2021 | -847.49% |
| Jun 30, 2021 | 4.38% |